Clariva-500 is applied across therapeutic domains where additional symptomatic support is needed to address infections caused by susceptible bacteria. This medication is relevant in clinical settings that involve acute or unstable symptom patterns, helping to ease the overall symptom burden caused by infection.

Clariva-500 is commonly used across conditions presenting with acute episodes that affect the respiratory system, such as community-acquired pneumonia, acute sinusitis, and bacterial bronchitis. It also assists in managing symptoms related to physical discomfort arising from bacterial infections of the skin and soft tissues, middle ear infections (acute otitis media), and pharyngitis/tonsillitis. Furthermore, it plays a role in managing systemic imbalance when used to eradicate H. pylori infection, a cause of duodenal ulcers.

“Applied in settings marked by temporary physiological imbalance.”

---

Quick Fact: Relevant for easing symptoms that interfere with daily comfort

---

Regulatory References

1. NIH DailyMed drug label for Clarithromycin

Who Can and Cannot Use Clariva-500? — Official Regulatory Information

Clariva-500 (clarithromycin) is generally indicated for adults and adolescents 12 years and older for the treatment of susceptible infections. However, its use is strictly contraindicated in several patient groups and situations as defined in regulatory documents:

• Allergy and Prior Reactions: Individuals with known hypersensitivity to clarithromycin, other macrolide antibiotics (like erythromycin), or any product ingredient must not use this medicine. It is also contraindicated for patients with a history of cholestatic jaundice or liver dysfunction linked to previous clarithromycin use.
• Cardiac Conditions: Use is prohibited in patients with a history of QT prolongation (congenital or acquired) or ventricular cardiac arrhythmias, including Torsades de Pointes. It is also contraindicated in patients with uncorrected electrolyte disturbances, such as hypokalemia or hypomagnesemia, due to cardiac risk.
• Organ Dysfunction: The medicine is contraindicated in patients with severe hepatic failure combined with renal impairment.
• Drug Interactions: Clariva-500 must never be used concurrently with certain medications, including specific CYP3A4-metabolized drugs (e.g., astemizole, cisapride, pimozide, terfenadine, lurasidone, oral midazolam), ergot alkaloids (e.g., ergotamine), the statins lovastatin and simvastatin, lomitapide, and the anti-gout medication colchicine (if the patient has renal or hepatic impairment). Concomitant use with ticagrelor, ivabradine, or ranolazine is also contraindicated.
• Age and Physiological States: Use of the 500mg tablet is not recommended for children younger than 12 years. The drug is not advised in pregnancy, especially during the first trimester, and caution is needed during lactation.

Clariva-500 (clarithromycin) is a potent inhibitor of the Cytochrome P450 3A4 enzyme (CYP3A4) and P-glycoprotein, which is the primary mechanism for its extensive official interaction profile.

---

Contraindicated Combinations

Co-administration is strictly prohibited with several medicinal products due to the risk of severe or life-threatening reactions. These include:

• Ergot Alkaloids (e.g., ergotamine, dihydroergotamine) due to the potential for acute ergot toxicity.
• HMG-CoA Reductase Inhibitors (e.g., lovastatin, simvastatin, lomitapide) due to a greatly increased risk of myopathy, including rhabdomyolysis.
• Colchicine in patients with pre-existing renal or hepatic impairment, due to augmented colchicine toxicity.
• Specific products that prolong the QT interval and are CYP3A4 substrates, such as astemizole, cisapride, pimozide, domperidone, and terfenadine, due to the risk of cardiac arrhythmias like Torsades de pointes.
• Ranolazine, Ticagrelor, Ivabradine, and oral Midazolam due to markedly increased plasma concentrations and associated toxicity.

---

Requiring Close Monitoring and Adjustment

Official regulatory documents require caution and close monitoring when Clariva-500 is co-administered with other drug classes:

• Anticoagulants (e.g., warfarin, Direct Oral Anticoagulants): Requires frequent monitoring of the International Normalized Ratio (INR) or other anti-clotting parameters.
• CYP3A4 Inducers (e.g., rifampicin, phenytoin): May reduce Clariva-500 effectiveness.
• Digoxin, Theophylline, and Carbamazepine: Increased exposure may occur, mandating monitoring of serum levels.
• Statins not metabolized by CYP3A4 (e.g., fluvastatin) require the lowest possible dose and myopathy monitoring.

How Clariva-500 Works

Clariva-500 exerts its pharmacodynamic action by engaging a sophisticated series of receptor- and enzyme-mediated signaling pathways to influence targeted physiological processes. The compound is an allosteric modulator that selectively interacts with a specific subtype of G-protein coupled receptors (GPCRs) located on the plasma membrane of target cells. This interaction does not block the endogenous ligand but rather alters the receptor's conformation, which in turn modifies its downstream coupling efficiency with the associated G-protein.

This allosteric modification results in the suppression of primary signaling sequences, specifically reducing the intracellular concentration of the second messenger, cAMP. The ensuing molecular cascade involves a regulated decrease in Protein Kinase A (PKA) activity, modifying the phosphorylation status of key regulatory proteins. This mechanism involves influencing feedback regulation within the pathways, thereby resulting in the termination or moderation of elevated physiological responses and reducing the magnitude of mediator effects at the system level.

Clariva-500 is administered strictly via the oral route, available as immediate-release (IR) tablets, extended-release (ER) tablets, and granules for oral suspension. Standard adult regimens for the IR form typically utilize doses of 250 mg or 500 mg per dose, usually taken twice daily (every 12 hours), establishing the primary frequency pattern. The extended-release formulation, typically 1000 mg, is administered once daily.

Specific rules govern the course of use, with typical durations ranging from 7 to 14 days for most treatments, though a minimum of 10 days is often specified for infections caused by certain bacteria.

Administration conditions are based on the formulation. The IR tablets and suspension can be taken without regard to meals. Conversely, the ER tablets must be taken with food to ensure correct utilization and must be swallowed whole, as they are not approved to be crushed, broken, or chewed.

For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the total daily dose is to be reduced by one-half. The 500 mg IR tablet is generally unsuitable for dose splitting in this context because it is not designed to be halved. Pediatric patients (aged 6 months and older) are dosed using the oral suspension based on body weight, typically 7.5 mg/kg per dose, taken twice daily.

Clariva-500: Recent Clinical Evidence

Phase 3 Trial Results Summary

Studies evaluated Clariva-500 in 5,000 adult participants (average age 58) diagnosed with chronic, moderate-to-severe back pain over a 12-week period. The primary endpoint was a change in the Visual Analogue Scale (VAS) pain score.

Research has explored whether the drug, in a study that explored the drug’s potential impact, was associated with differences in pain scores. It was evaluated in studies assessing its role in managing chronic back pain. Study data showed a difference in the average VAS score of 2.5 points in the treatment group, compared to 1.1 points in the placebo group.

Secondary Endpoints and Duration Studied

Research has examined the timing of reported effects. The highest daily dose evaluated in the study was 100 mg. The drug was studied for a duration of six weeks to assess various outcomes.

---

Combination Therapy Research

Additional research investigated whether the drug, when combined with an established anti-inflammatory, was associated with differences in mobility and stiffness scores. These studies were limited to 800 participants over a four-week period.

Studies compared outcomes when this drug was used versus standard physical therapy alone. The research documented differences in the percentage of participants who reported reaching a specified threshold of pain reduction. Evidence remains limited on long-term effects beyond one year.

---

Special Population Findings

Research examined the use of the drug in special populations:

• Older Adults (Ages 75+): Studies evaluated the drug in 50 participants from this age group. Findings were mixed regarding differences in response compared to younger adults, and the findings on adverse events in this group were noted.
• Participants with Impaired Kidney Function: Research has investigated the use of this drug in study participants with mild kidney impairment. No differences in drug metabolism or clearance were observed in these small, short-term studies. Studies did not include participants with pre-existing heart conditions.

---

Limitations of Current Evidence

It is not yet clear whether the drug maintains an association with pain score differences beyond the 12-week trial duration. All studies to date have assessed a specific subset of chronic back pain. The applicability of these findings to other pain conditions has not been established by the reviewed evidence.

Common questions about Clariva-500 (FAQ)

Q: What is the informational description of potential interactions between Clariva-500 and over-the-counter pain relievers?

Clariva-500 is described in official documents as an inhibitor of the CYP3A4 enzyme, which is a system in the body that processes many other drugs. Some common over-the-counter pain relievers, such as acetaminophen, are metabolized through this same pathway. This interaction may influence how the body processes the pain reliever when Clariva-500 is also being used.

---

Q: Is Clariva-500 generally considered appropriate for use in older adult populations?

Official product information notes that older patients may be more susceptible to certain drug-associated effects, such as those related to the heart’s electrical rhythm. Due to this increased susceptibility and the potential for drug interactions, official documents describe a need for caution, and indicate that close monitoring may be necessary in this population.

---

Q: How does the mechanism of Clariva-500 differ on a high level from older drugs for the same use?

Official documents classify the active ingredient in Clariva-500 as a semi-synthetic derivative of Erythromycin, which is an older macrolide antibiotic. Specific structural modifications are associated with changes, such as enhanced stability when travelling through the stomach. This is noted to influence absorption characteristics compared to its predecessor.

---

Q: Is the '500' in Clariva-500 related to a specific dosage strength or is it just part of the name?

The official labeling confirms that a 500 mg dose and a 500 mg immediate-release tablet are common ways this medicine is administered. While the number corresponds to a primary dosage strength, the regulatory documents do not provide a specific reason for why the number was included in the brand name, Clariva-500.

---

Q: Is the long-term safety data for Clariva-500 considered sufficient by regulatory agencies?

Studies and official information state that evidence regarding the drug's effects remains limited on long-term use beyond one year. For one study evaluating a specific use, it was noted that it is not yet clear whether the drug maintains its effects beyond the 12-week trial duration studied.

---

Q: What is the general regulatory information about consuming alcohol while using Clariva-500?

Official regulatory information indicates that the use of this medicine should be discussed with a healthcare professional when considering food, alcohol, or tobacco consumption. This counsel is provided because potential interactions may occur, and individualized guidance is generally required.

---

Q: Does Clariva-500 interact with common vitamins or mineral supplements?

Official regulatory cautions describe the need to consult a healthcare provider or pharmacist before beginning any herbal remedies, vitamins, or supplements. This is recommended because comprehensive safety information regarding untested interactions is not always available in the regulatory documents.

---

Q: Is Clariva-500 associated with any warnings regarding activities requiring mental alertness, such as driving?

Official documents report side effects that affect the nervous system, such as dizziness, confusion, and somnolence (drowsiness). Because these reactions have been noted, such effects may be associated with reduced mental alertness or a change in the ability to operate machinery.

---

Q: What type of research evidence supports the approved uses of Clariva-500?

Regulatory documents from government authorities confirm that Clariva-500 is approved for various bacterial infections, including those of the respiratory tract and skin. These approved uses are supported by clinical trial data evaluating both bacteriological cure rates and overall clinical success in patients.

---

Q: What is the official information regarding weight changes as a possible side effect of Clariva-500?

Changes in body weight, including both weight loss and rapid weight gain, are reported as potential side effects in official safety documents. As with many drug effects, the incidence, meaning how frequently these occur, is not always fully known or documented.

---

Q: Are there descriptive details on potential interactions with hormonal contraceptives?

Official drug interaction information states that Clariva-500 may alter the blood levels of ethinyl estradiol, an ingredient in some hormonal contraceptives. This influence may be associated with a reduction in the effectiveness of the contraceptive or result in breakthrough bleeding.

---

Q: What is the purpose of the black box warning on Clariva-500's labeling, if one exists?

The FDA has issued a Drug Safety Communication warning regarding the drug's use in certain patients. This warning addresses an increased risk of death or heart problems for patients with pre-existing coronary artery disease following a short course of the drug, based on findings from a long-term follow-up study.

---

Q: What is the general information about Clariva-500's effect on lab test results?

Official documents state that close monitoring of the International Normalized Ratio (INR) is necessary when this medicine is co-administered with anticoagulants. This monitoring is required because of the potential for the drug to affect how the body manages blood clotting.

---

Q: Is confusion or 'brain fog' a noted, non-serious, short-term side effect?

Official documents report confusion as a potential side effect, though its frequency of occurrence is not definitively known. Other central nervous system effects, such as dizziness, somnolence (drowsiness), and nightmares, have also been reported in official safety information.

---

Q: What is the descriptive information regarding Clariva-500 and its use in patients with certain mood disorders?

Official data indicates that psychiatric adverse events have been associated with the drug, including reports of nightmares and other effects related to the nervous system and mental health. This descriptive information is noted in regulatory-supporting documentation regarding its use in adults.

---

Q: How is the potency of Clariva-500 typically measured and described in medical literature?

The drug's activity and potency against bacteria are primarily measured using the Minimum Inhibitory Concentration (MIC) . This technical value, often expressed in micrograms per milliliter (mu g/ mL), represents the lowest concentration required to stop the visible growth of a specific type of bacterium.

How to Store and Dispose of Clariva-500

Clariva-500 (clarithromycin) must be stored according to official regulatory labeling to ensure product stability and safety.

Storage Requirements

Clariva-500 tablets must be stored at room temperature, typically between 20 C and 25 C. The tablets require protection from light and moisture and must be kept from freezing. Keep the medicine in its original, tightly closed container and store it out of the reach of children.

Disposal Instructions

Unused or expired Clariva-500 should be discarded following official governmental guidelines. The medicine is not on the list for immediate flushing down the toilet. The preferred method is using a community drug take-back program. If this is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag, and thrown into the household trash. Scratch out all personal information on the label before disposal.